避孕与癌症:CNGOF避孕指南
该指南基于PubMed/Medline和Cochrane图书馆的系统综述,旨在汇总激素避孕与癌症风险的知识,并为癌症治疗期间及治疗后避孕提供推荐。总体而言,激素避孕使用者癌症总发病率或死亡率未增加;雌孕激素联合避孕药与使用期间乳腺癌风险增加相关,与子宫内膜癌、卵巢癌、淋巴或造血系统癌症风险降低相关且停药后持续,与结直肠癌风险降低相关。癌症风险信息应纳入避孕咨询,但在无特定癌症风险因素的女性中不影响处方,因风险/获益平衡为正。癌症诊断时所有未绝经女性在治疗期间及治疗后均需避孕,选择前需考虑肿瘤背景相关的血栓栓塞、免疫或呕吐风险。乳腺癌后所有激素避孕均禁忌,无论治疗间隔、激素受体状态和组织学亚型。结直肠癌或甲状腺癌后无数据限制激素或非激素避孕使用。宫颈癌、黑色素瘤、肺癌、中枢神经系统肿瘤或胸部放疗后避孕选择证据不足。既往激素敏感性癌症女性需紧急避孕时,应优先选择非激素铜宫内节育器。
要点
- 乳腺癌后所有激素避孕均禁忌,无论治疗间隔、激素受体状态和组织学亚型。
- 癌症诊断时所有未绝经女性在治疗期间及治疗后均需避孕,选择需考虑肿瘤背景相关的血栓栓塞、免疫或呕吐风险。
- 激素避孕使用者癌症总发病率或死亡率未增加;雌孕激素联合避孕药使用期间乳腺癌风险增加,但子宫内膜癌、卵巢癌、淋巴或造血系统癌症及结直肠癌风险降低。
- 既往激素敏感性癌症女性需紧急避孕时,应优先选择非激素铜宫内节育器。
- 结直肠癌或甲状腺癌后无数据限制激素或非激素避孕使用;宫颈癌、黑色素瘤、肺癌、中枢神经系统肿瘤或胸部放疗后避孕选择证据不足。
适用人群与场景
- 希望避孕的女性,包括无特定癌症风险因素者。
- 癌症诊断时所有未绝经女性,治疗期间及治疗后。
- 既往接受过癌症治疗的女性,包括激素敏感性癌症患者需紧急避孕时。
处置流程与药物剂量
- 癌症风险信息应作为希望避孕患者系统信息的一部分,但在无特定癌症风险因素女性中不影响避孕处方,因风险/获益平衡为正。
- 癌症诊断时所有未绝经女性在治疗期间及治疗后均应避孕,选择前需考虑肿瘤背景相关的血栓栓塞、免疫或呕吐风险。
- 乳腺癌后所有激素避孕均禁忌,无论治疗间隔、激素受体状态和组织学亚型。
- 结直肠癌或甲状腺癌后无数据限制激素或非激素避孕使用。
- 宫颈癌、黑色素瘤、肺癌、中枢神经系统肿瘤或胸部放疗后避孕选择证据不足。
- 既往激素敏感性癌症女性需紧急避孕时,应优先选择非激素铜宫内节育器。
研究设计与关键结果
- 系统综述显示,激素避孕使用者癌症总发病率或死亡率未增加。
- 雌孕激素联合避孕药使用与使用期间乳腺癌风险增加相关,与子宫内膜癌、卵巢癌、淋巴或造血系统癌症风险降低相关且停药后持续,与结直肠癌风险降低相关。
证据类型、等级与局限
- 证据类型:基于PubMed/Medline和Cochrane图书馆系统综述的指南。
- 局限:宫颈癌、黑色素瘤、肺癌、中枢神经系统肿瘤或胸部放疗后避孕选择相关文献数据不足。
对床旁实践的改变
- 无特定癌症风险因素女性,癌症风险信息不改变激素避孕处方。
- 乳腺癌后禁用所有激素避孕,需选择非激素避孕方法。
- 癌症治疗期间及治疗后需避孕,选择时考虑血栓栓塞、免疫或呕吐风险。
- 既往激素敏感性癌症女性紧急避孕时优选铜宫内节育器。
- 结直肠癌或甲状腺癌后不限制激素或非激素避孕使用。
指南或共识出处
- CNGOF避孕指南(Gynecol Obstet Fertil Senol)
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To synthesize knowledge on cancer risks related to hormonal contraception and to propose recommendations on contraception during treatment and after cancer.
METHODS: A systematic review of the literature about hormonal contraception and cancer was conducted on PubMed/Medline and the Cochrane Library.
RESULTS: Overall, there is no increase in cancer (all types together) incidence or mortality among hormonal contraceptive users. Estroprogestin combined contraceptive use is associated with an increased risk of breast cancer (during use), and with a reduced risk of endometrial, ovarian, lymphatic or hematopoietic cancers that persist after discontinuation, and a decreased risk of colorectal cancer. Information on cancer risk is part of the systematic information given to patients wishing contraception. However, these data will not influence its prescription, considering the positive risk/benefit balance in women without specific cancer risk factor. Contraception is required during and after cancer treatment in every non-menopausal woman at cancer diagnosis. Specific thromboembolic, immunologic or vomiting risks due to the oncological context should be taken into account before the contraceptive choice. All hormonal contraceptives are contra-indicated after breast cancer, regardless of the delay since treatment, hormone receptor status and histological subtype. There is no data in the literature to limit hormonal or non-hormonal contraceptive use after colorectal or thyroid cancer. There was insufficient data in the literature to propose recommendations on contraceptive choice after cervical cancer, melanoma, lung cancer, tumor of the central nervous system, or after thoracic irradiation. If an emergency contraception is needed in a woman previously treated for a hormone-sensitive cancer, a non-hormonal copper intrauterine device should be preferred.
CONCLUSIONS: Information on cancer risk is part of the patient's information but does not influence the prescription of contraception in the absence of any specific risk factor. Contraception should be proposed in every woman treated or previously treated for cancer. The whole context should be taken into account to choose a tailored contraception.
参考来源
- Pragout D, Laurence V, Baffet H, et al. [Contraception and cancer: CNGOF Contraception Guidelines]. Gynecol Obstet Fertil Senol. 2018. PMID: 30385358. doi:10.1016/j.gofs.2018.10.010
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。